Enterprise Value

459.3M

Cash

371.4M

Avg Qtr Burn

N/A

Short % of Float

15.06%

Insider Ownership

4.02%

Institutional Own.

32.41%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OMIDRIA (phenylephrine and ketorolac intraocular solution) Details
Cataract surgery or intraocular lens replacement

Approved

Quarterly sales

BLA

Resubmission

Phase 3

Data readout

Narsoplimab (MASP-2 inhibitor, lectin pathway) Details
Kidney disease, IgA nephropathy

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 2

Data readout

OMS906 Details
Paroxysmal nocturnal hemoglobinuria , Blood disorder

Phase 1b

Data readout

Narsoplimab (MASP-2 inhibitor, lectin pathway) Details
Kidney disease, Diabetic macular edema, Diabetes

Failed

Discontinued